Abstract
The female reproductive lifespan depends on egg quality, particularly euploidy. Mistakes in meiosis leading to egg aneuploidy are common, but the genetic landscape causing this is not well understood due to limited phenotypic data. We identify genetic determinants of reproductive aging via egg aneuploidy using a biobank of maternal exomes linked with maternal age and embryonic aneuploidy data. We found 404 genes with variants enriched in individuals with high egg aneuploidy rates and implicate kinesin protein family genes in aneuploidy risk. Experimental perturbations showed that motor domain variants in these genes increase aneuploidy in mouse oocytes. A knock-in mouse model validated that a specific variant in kinesin KIF18A accelerates reproductive aging and diminishes fertility. These findings suggest potential non-invasive biomarkers for egg quality, aiding personalized fertility medicine.
One sentence summary The study identifies novel genetic determinants of reproductive aging linked to egg aneuploidy by analyzing maternal exomes and demonstrates that variants in kinesin genes, specifically KIF18A, contribute to increased aneuploidy and accelerated reproductive aging, offering potential for personalized fertility medicine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH grant R01HD091331 to KS and JX. LB was supported by NIH fellowship F30HD107976, the Foundation for Womens Wellness, and NIH grant T32GM139804. The Tolic lab is funded by the European Research Council (ERC Synergy Grant, GA Number 855158), the Croatian Science Foundation (HRZZ) through Swiss-Croatian Bilateral Projects (project IPCH 2022 10 9344), and projects cofinanced by the Croatian Government and the European Union through the European Regional Development Fund the Competitiveness and Cohesion Operational Programme: IPSted (Grant KK.01.1.1.04.0057) and QuantiXLie Center of Excellence (Grant KK.01.1.1.01.0004).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patient DNA samples were obtained from Reproductive Medicine Associates of New Jersey (RMANJ) DNA Bank, and the project was approved by IRB #RMA1-09-165 at Copernicus Group IRB and IRB #Pro2018000106 at Rutgers University
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
